FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, in particular to an antibody molecule, which binds to human CD73, to its production method, as well as to a composition containing it. Nucleic acid encoding a heavy chain variable domain and nucleic acid encoding a light chain variable domain of the above-mentioned antibody molecule, as well as a cell containing it and a vector are also disclosed. The invention also relates to a method for detection of CD73 in a biological sample or in a subject, providing for the use of the above-mentioned antibody molecule, which binds to human CD73.
EFFECT: invention is effective for stimulation of an immune response in a subject, as well as for the treatment of cancer in a subject.
30 cl, 28 dwg, 26 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BINDING MOLECULES SPECIFIC FOR CD73, AND METHODS OF THEIR APPLICATION | 2015 |
|
RU2730665C2 |
| ANTIBODIES TO ENTPD2, TYPES OF COMBINATION THERAPY AND METHODS FOR USING ANTIBODIES AND TYPES OF COMBINATION THERAPY | 2019 |
|
RU2790991C2 |
| CD73 BLOCKING ANTIBODIES | 2020 |
|
RU2819204C2 |
| FUSED PROTEIN CONSTRUCTS FOR COMPLEMENT-RELATED DISEASE | 2019 |
|
RU2824402C2 |
| ANTIBODIES SUITABLE FOR PASSIVE IMMUNIZATION AGAINST INFLUENZA, AND COMPOSITIONS THEREOF, COMBINATIONS AND METHODS OF USING | 2015 |
|
RU2720282C1 |
| STAPHYLOCOCCUS AUREUS CLUMPING FACTOR A (ClfA) ANTIBODY | 2019 |
|
RU2818805C2 |
| ANTIBODIES TO PD-1 AND THEIR APPLICATION | 2017 |
|
RU2761640C2 |
| ANTIBODY TO HUMAN CD73 | 2017 |
|
RU2754058C2 |
| CRYSTAL STRUCTURE OF GREMLIN-1 AND INHIBITORY ANTIBODY | 2017 |
|
RU2769285C2 |
| COMBINED MEDICINAL PRODUCTS TARGETING PD-1, TIM-3 AND LAG-3 | 2018 |
|
RU2795232C2 |
